Filing Flows › InspireMD (NSPR) › R&D spending
InspireMD (NSPR) R&D spending by quarter
InspireMD's R&D spending was $4.3M in Q2 2026 (second quarter 2026), -10% from Q1 2026. Over the last 7 quarters it ranged from $3.5M (Q4 2025) to $4.8M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.3M | -10% | +12% |
| Q1 2026 | $4.8M | +37% | +17% |
| Q4 2025 | $3.5M | -4% | -6% |
| Q3 2025 | $3.6M | -5% | — |
| Q2 2025 | $3.8M | -6% | — |
| Q1 2025 | $4.1M | +10% | — |
| Q4 2024 | $3.7M | — | — |
Q2 2026 at a glance
InspireMD, Q2 2026: revenue $1.8M (-0.4% year over year), operating margin -815.6%, net loss $14.3M, operating cash flow −$10.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is InspireMD's R&D spending?
InspireMD's R&D spending was $4.3M in Q2 2026 (second quarter 2026), -10% from Q1 2026.
How has InspireMD's R&D spending changed?
Over the last 7 quarters it ranged from $3.5M (Q4 2025) to $4.8M (Q1 2026).